DAVY VIEW

Amryt’s market update is encouraging, showing strong revenue growth, a robust balance sheet and COVID-19 readiness. On a pro-forma basis, FY 19 revenues grew 13% - better than expected. Cash balance increased to $65m with debt maturities not until 2024 and 2025. Regards COVID-19, Amryt has a robust, 12-month supply of product for patients and has experienced no logistical difficulties so far. The recruitment of patients for the AP101 Phase III trial is ongoing with the company having flexibility to focus on geographies less impacted by COVID-19. FY 19 results are scheduled for release in early April.